Quantcast

Latest Quinazolines Stories

2011-05-26 09:14:00

OMAHA, Neb., May 26, 2011 /PRNewswire/ -- Transgenomic, Inc. (OTC/BB: TBIO) announced today that it has acquired an exclusive worldwide license to Montefiore Medical Center's (Bronx, NY, US) patent application, "Method of Determining the Sensitivity of Cancer Cells to EGFR Inhibitors including cetuximab, panitumumab and erlotinib". The invention relates to the discovery by Montefiore scientists and collaborators that tumor-specific mutations in the genes PIK3CA and PTEN can aid in...

2011-05-25 11:28:00

RIDGEFIELD, Conn., May 25 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. will present new phase Ib data at the 2011 American Society of Clinical Oncology (ASCO) annual meeting in Chicago (June 3-7) that indicates combining its investigational therapy afatinib (BIBW 2992) with cetuximab at the maximum tested dose controlled disease in all (n=22) treated epidermal growth factor receptor (EGFR)-mutation positive patients with non-small cell lung cancer (NSCLC) who developed...

2011-05-19 13:48:56

A subset of breast cancer patients who have tumors overexpressing a protein called the human epidermal growth factor receptor 2 (HER-2 positive) may benefit from a combination of targeted treatments and may not need chemotherapy, said researchers from the Lester and Sue Smith Breast Center at Baylor College of Medicine on behalf of the Translational Breast Cancer Research Consortium in an abstract released today by the American Society of Clinical Oncology. Dr. Jenny Chang, previously with...

2011-04-28 15:34:00

BROOMFIELD, Colo., April 28, 2011 /PRNewswire/ -- Biodesix announces the enrollment of initial subjects into CASTLE, the inaugural study of the Addario Lung Cancer Medical Institute (ALCMI, pronounced as "Alchemy"). The CASTLE (Collaborative Advanced Stage Tissue Lung Cancer) study is recruiting a minimum of 250 subjects over two years among academic and community medical centers in the United States. The study collects biospecimens and data from lung cancer patients in order to facilitate...

2011-04-04 17:02:41

UT MD Anderson scientists find new biomarkers for erlotinib treatment Two sets of gene expression profiles predict response to a common lung cancer drug for patients that have no guiding indicators for their treatment now, scientists from The University of Texas MD Anderson Cancer Center report at the AACR 102nd Annual Meeting. "The only way we have to predict erlotinib's treatment benefit for patients now is by checking for certain mutations and amplifications of the epidermal growth factor...

2011-03-23 21:42:43

Repeat biopsies may provide information critical to guiding treatment decisions A detailed analysis of lung tumors that became resistant to targeted therapy drugs has revealed two previously unreported resistance mechanisms. In a report in the March 23 Science Translational Medicine, investigators from the Massachusetts General Hospital (MGH) Cancer Center also describe how the cellular nature of some tumors actually changes in response to treatment and find that resistance-conferring...

2011-03-10 23:42:52

LSU oncologist Vince D. Cataldo, MD, is the lead author of a review article reporting two chemotherapy drugs now indicated for second and third-line therapy in patients with advanced non-small-cell lung cancer are remarkably effective in treating a certain subset of these patients. Dr. Cataldo, a Clinical Assistant Professor of Medicine at LSU Health Sciences Center New Orleans School of Medicine, practicing at LSU's Earl K. Long Medical Center and Hematology-Oncology Clinic in Baton Rouge,...

2011-02-28 13:29:37

European Multidisciplinary Conference in Thoracic Oncology news The targeted cancer drug erlotinib has comparable efficacy to chemotherapy, and is better tolerated, in hard-to-treat cases where a patient's cancer has progressed quickly after treatment with first-line therapy, the results of a new phase III trial show. Dr Tudor Ciuleanu from the Institute of Oncology Ion Chiricuta, Cluj-Napoca, Romania, reported this finding from the international TITAN study at the European Multidisciplinary...

2011-02-25 13:16:36

European Multidisciplinary Conference in Thoracic Oncology news Spanish researchers have identified a gene whose expression level strongly predicts how well certain lung cancer patients will respond to treatment with the drug erlotinib. Dr Rafael Rosell and colleagues reported their findings at the European Multidisciplinary Conference in Thoracic Oncology (EMCTO), 24-26 February 2011 in Lugano, Switzerland. The researchers studied 55 patients with non-small cell lung cancer, whose tumors had...

2011-02-22 07:37:00

SAN DIEGO, Feb. 22, 2011 /PRNewswire/ -- Proacta Incorporated and Yakult Honsha Co., Ltd. (Tokyo: 2267) today announced the execution of a definitive agreement relating to the collaborative research, development and commercialization of Proacta's PR509, a hypoxia-activated pro-drug for the treatment of cancer. (Logo: http://photos.prnewswire.com/prnh/20110222/LA50556LOGO-a ) (Logo: http://photos.prnewswire.com/prnh/20110222/LA50556LOGO-b ) "We have worked diligently to arrive at this...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related